AU2016210889C1 - Anti-transthyretin antibodies - Google Patents

Anti-transthyretin antibodies Download PDF

Info

Publication number
AU2016210889C1
AU2016210889C1 AU2016210889A AU2016210889A AU2016210889C1 AU 2016210889 C1 AU2016210889 C1 AU 2016210889C1 AU 2016210889 A AU2016210889 A AU 2016210889A AU 2016210889 A AU2016210889 A AU 2016210889A AU 2016210889 C1 AU2016210889 C1 AU 2016210889C1
Authority
AU
Australia
Prior art keywords
antibody
ttr
seq
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016210889A
Other languages
English (en)
Other versions
AU2016210889B2 (en
AU2016210889A1 (en
Inventor
Avijit Chakrabartty
Jeffrey N. Higaki
Tarlochan S. Nijjar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Novo Nordisk AS
Original Assignee
University Health Network
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network, Novo Nordisk AS filed Critical University Health Network
Publication of AU2016210889A1 publication Critical patent/AU2016210889A1/en
Publication of AU2016210889B2 publication Critical patent/AU2016210889B2/en
Application granted granted Critical
Publication of AU2016210889C1 publication Critical patent/AU2016210889C1/en
Assigned to UNIVERSITY HEALTH NETWORK, NEOTOPE NEUROSCIENCE LIMITED reassignment UNIVERSITY HEALTH NETWORK Request for Assignment Assignors: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
Assigned to NOVO NORDISK A/S, UNIVERSITY HEALTH NETWORK (UHN) reassignment NOVO NORDISK A/S Request for Assignment Assignors: NEOTOPE NEUROSCIENCE LIMITED, UNIVERSITY HEALTH NETWORK
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016210889A 2015-01-28 2016-01-28 Anti-transthyretin antibodies Ceased AU2016210889C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562109004P 2015-01-28 2015-01-28
US62/109,004 2015-01-28
US201562266555P 2015-12-11 2015-12-11
US62/266,555 2015-12-11
PCT/IB2016/050416 WO2016120811A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (3)

Publication Number Publication Date
AU2016210889A1 AU2016210889A1 (en) 2017-08-10
AU2016210889B2 AU2016210889B2 (en) 2021-10-21
AU2016210889C1 true AU2016210889C1 (en) 2022-02-10

Family

ID=55300737

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016210889A Ceased AU2016210889C1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Country Status (25)

Country Link
US (1) US20160257737A1 (cg-RX-API-DMAC7.html)
EP (1) EP3250593B1 (cg-RX-API-DMAC7.html)
JP (1) JP7101927B2 (cg-RX-API-DMAC7.html)
KR (1) KR102649788B1 (cg-RX-API-DMAC7.html)
CN (1) CN107406500B (cg-RX-API-DMAC7.html)
AU (1) AU2016210889C1 (cg-RX-API-DMAC7.html)
CA (1) CA2974993A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017008482A2 (cg-RX-API-DMAC7.html)
CU (1) CU20170098A7 (cg-RX-API-DMAC7.html)
DK (1) DK3250593T3 (cg-RX-API-DMAC7.html)
EA (1) EA036014B1 (cg-RX-API-DMAC7.html)
ES (1) ES2925716T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220918T1 (cg-RX-API-DMAC7.html)
HU (1) HUE059592T2 (cg-RX-API-DMAC7.html)
MX (1) MX389911B (cg-RX-API-DMAC7.html)
MY (1) MY193701A (cg-RX-API-DMAC7.html)
PE (1) PE20180218A1 (cg-RX-API-DMAC7.html)
PL (1) PL3250593T3 (cg-RX-API-DMAC7.html)
PT (1) PT3250593T (cg-RX-API-DMAC7.html)
RS (1) RS63513B1 (cg-RX-API-DMAC7.html)
SA (1) SA517381981B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201906696RA (cg-RX-API-DMAC7.html)
SI (1) SI3250593T1 (cg-RX-API-DMAC7.html)
TW (2) TWI769570B (cg-RX-API-DMAC7.html)
WO (1) WO2016120811A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7017013B2 (ja) * 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
KR102956517B1 (ko) 2017-10-04 2026-04-23 암젠 인크 트랜스타이레틴 면역글로불린 융합
SG11202002489YA (en) 2017-10-06 2020-04-29 Prothena Biosciences Ltd Anti-transthyretin antibodies
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
MA51223A (fr) 2017-11-29 2020-10-07 Prothena Biosciences Ltd Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine
US12006357B2 (en) 2018-06-26 2024-06-11 Mor Research Applications Ltd. Transthyretin antibodies and uses thereof
CN111018976B (zh) * 2018-10-10 2022-04-01 东莞市朋志生物科技有限公司 一种抗人心肌肌钙蛋白i的重组抗体
EP3876713B1 (en) * 2018-11-09 2024-10-02 Neurimmune AG Patient-derived amyloid xenograft rodent model
TWI917325B (zh) * 2019-06-04 2026-03-11 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
US20220324924A1 (en) * 2019-07-08 2022-10-13 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
AU2021297540A1 (en) 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
CA3195512A1 (en) 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
CN116635024A (zh) * 2020-10-14 2023-08-22 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
MX2023006596A (es) * 2020-12-03 2023-06-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica de anticuerpo anti-tslp y uso de la misma.
US20240052050A1 (en) * 2020-12-16 2024-02-15 Merus N.V. Multispecific antibodies for the treatment of cancer
CN117916599A (zh) 2021-09-07 2024-04-19 美国西门子医学诊断股份有限公司 生物标记物组合物及其使用方法
CN116804186B (zh) * 2023-07-05 2023-12-22 中国兽医药品监察所 一种抗鸡传染性贫血病毒单克隆抗体杂交瘤细胞株、单克隆抗体、试剂或试剂盒及其应用
CN122374011A (zh) 2023-12-15 2026-07-10 诺和诺德股份有限公司 稳定的液体制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056904A1 (en) * 2012-08-24 2014-02-27 University Health Network Antibodies to TTR and Methods of Use

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
DE50308030D1 (de) 2002-11-29 2007-10-04 Boehringer Ingelheim Pharma Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
EP1820022B1 (en) 2004-11-10 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
WO2007124345A2 (en) 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
EP2522730A1 (en) 2007-03-02 2012-11-14 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP2010195710A (ja) * 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
JP2016514091A (ja) * 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス, インコーポレイテッド トランスサイレチン抗体およびその使用
US20160168235A1 (en) * 2013-07-19 2016-06-16 Board Of Regents Of The University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056904A1 (en) * 2012-08-24 2014-02-27 University Health Network Antibodies to TTR and Methods of Use

Also Published As

Publication number Publication date
AU2016210889B2 (en) 2021-10-21
KR102649788B1 (ko) 2024-03-20
CN107406500B (zh) 2022-02-25
HRP20220918T1 (hr) 2022-10-28
US20160257737A1 (en) 2016-09-08
RS63513B1 (sr) 2022-09-30
EA201791710A1 (ru) 2017-12-29
SI3250593T1 (sl) 2022-09-30
SG10201906696RA (en) 2019-08-27
MX2017009803A (es) 2018-08-15
EP3250593B1 (en) 2022-06-22
ES2925716T3 (es) 2022-10-19
TWI769570B (zh) 2022-07-01
TW201636371A (zh) 2016-10-16
HUE059592T2 (hu) 2022-11-28
SG11201706126WA (en) 2017-08-30
EA036014B1 (ru) 2020-09-14
MX389911B (es) 2025-03-04
AU2016210889A1 (en) 2017-08-10
TWI711631B (zh) 2020-12-01
JP2018510617A (ja) 2018-04-19
WO2016120811A1 (en) 2016-08-04
BR112017016345A2 (pt) 2018-03-27
TW202110896A (zh) 2021-03-16
CO2017008482A2 (es) 2018-01-16
KR20170120608A (ko) 2017-10-31
MY193701A (en) 2022-10-25
EP3250593A1 (en) 2017-12-06
CN107406500A (zh) 2017-11-28
JP7101927B2 (ja) 2022-07-19
PE20180218A1 (es) 2018-01-31
CU20170098A7 (es) 2018-03-13
PT3250593T (pt) 2022-08-31
SA517381981B1 (ar) 2022-05-17
DK3250593T3 (da) 2022-08-22
CA2974993A1 (en) 2016-08-04
PL3250593T3 (pl) 2022-09-19

Similar Documents

Publication Publication Date Title
AU2016210889B2 (en) Anti-transthyretin antibodies
AU2016210888C1 (en) Anti-transthyretin antibodies
AU2016210887B2 (en) Anti-transthyretin antibodies
CN111315213B (zh) 抗甲状腺素运载蛋白抗体
AU2018345807B2 (en) Methods of detecting transthyretin
CN109415432B (zh) Tau免疫疗法
US20210188956A1 (en) Anti-transthyretin antibodies
KR20150129736A (ko) Tau 면역치료제
US11267878B2 (en) Anti-transthyretin antibodies
WO2018007924A2 (en) Anti-transthyretin antibodies
HK1240247A1 (en) Anti‐transthyretin antibodies
HK1240247B (en) Anti‐transthyretin antibodies

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 NOV 2021

FGA Letters patent sealed or granted (standard patent)
PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITY HEALTH NETWORK

Free format text: FORMER APPLICANT(S): UNIVERSITY HEALTH NETWORK; PROTHENA BIOSCIENCES LIMITED

Owner name: NEOTOPE NEUROSCIENCE LIMITED

Free format text: FORMER APPLICANT(S): UNIVERSITY HEALTH NETWORK; PROTHENA BIOSCIENCES LIMITED

PC Assignment registered

Owner name: UNIVERSITY HEALTH NETWORK (UHN)

Free format text: FORMER OWNER(S): NEOTOPE NEUROSCIENCE LIMITED; UNIVERSITY HEALTH NETWORK

Owner name: NOVO NORDISK A/S

Free format text: FORMER OWNER(S): NEOTOPE NEUROSCIENCE LIMITED; UNIVERSITY HEALTH NETWORK